Biological Activities of a Recombinant Adenovirus P53 (Sch 58500) Administered by Hepatic Arterial Infusion in a Phase 1 Colorectal Cancer Trial

Posted: 10 May 2018

See all articles by Jeremy Shinoda

Jeremy Shinoda

Cordant Health Solutions

Shu Fen Wen

Canji, Inc. - Department of Process Sciences

Dan Maneval

Canji, Inc. - Department of Pharmacology

Date Written: August 03, 2005

Abstract

The major focus of intrahepatic arterial (IHA) administration of adenoviruses (Ad) has been on safety. Currently, there is little published data on the biological responses to Ad when administered via this route. As part of a Phase I study, we evaluated biological responses to a replication-defective adenovirus encoding the p53 transgene (SCH 58500) when administered by hepatic arterial infusion to patients with primarily colorectal cancer metastatic to the liver. In analyzing biological responses to the Ad vector, we found that both total and neutralizing Ad antibodies increased weeks after SCH 58500 infusion. The fold increase in antibody titers was not dependent on SCH 58500 dosage. The proinflammatory cytokine interleukin-6 (IL-6) transiently peaked within 6 h of dosing. The cytokine sTNF-R2 showed elevation by 24 h post-treatment, and fold increases were directly related to SCH 58500 doses. Cytokines TNF-α, IL-1β, and sTNF-R1 showed no increased levels over 24 h. Predose antibody levels did not appear to predict transduction, nor did serum Ad neutralizing factor (SNF). Delivery of SCH 58500 to tumor tissue occurred, though we found distribution more predominantly in liver tissues, as opposed to tumors. RT-PCR showed significantly higher expression levels (P<0.0001, ANOVA) for adenovirus type 2 and 5 receptor (CAR) in liver tissues, suggesting a correlation with transduction. Evidence of tumor-specific apoptotic activity was provided by laser scanning cytometry, which determined a coincidence of elevated nuclear p53 protein expression with apoptosis in patient tissue. IHA administration of a replication defective adenovirus is a feasible mode of delivery, allowing for exogenous transfer of the p53 gene into target tissues, with evidence of functional p53. Limited and transient inflammatory responses to the drug occurred, but pre-existing immunity to Ad did not preclude SCH 58500 delivery.

Suggested Citation

Shinoda, Jeremy and Wen, Shu Fen and Maneval, Dan, Biological Activities of a Recombinant Adenovirus P53 (Sch 58500) Administered by Hepatic Arterial Infusion in a Phase 1 Colorectal Cancer Trial (August 03, 2005). Available at SSRN: https://ssrn.com/abstract=3168780

Jeremy Shinoda (Contact Author)

Cordant Health Solutions ( email )

United States

HOME PAGE: http://www.cordantsolutions.com

Shu Fen Wen

Canji, Inc. - Department of Process Sciences

CA 92121
United States

Dan Maneval

Canji, Inc. - Department of Pharmacology

CA 92121
United States

Register to save articles to
your library

Register

Paper statistics

Abstract Views
50
PlumX Metrics